OBJECTIVES: Our objective was to characterize longitudinal patterns of viraemia and factors associated with viral suppression in people with HIV and low-level viraemia (LLV) during antiretroviral therapy (ART).METHODS: We included people with HIV in the EuResist Integrated Database with LLV following ART initiation after 2005. LLV was defined as two or more consecutive viral load (VL) measurements of 51-199 copies/mL 30-365 days apart after >12 months of ART. Viraemia patterns were analyzed over 24 months. Factors associated with viral suppression at 12 months after LLV episodes were identified using univariable and multivariable logistic regression.RESULTS: Of 25 113 people with HIV, 2474 (9.9%) had LLV. Among 1387 participants with 24 mon...
Background: The rate, predictors and outcome following episodes of low-level viral rebound (LLVR) in...
BACKGROUND: Management of persistent low-level viraemia (pLLV) in patients on combined antiretrovira...
Background: Few individuals commencing antiretroviral therapy (ART) in primary HIV infection (PHI) m...
OBJECTIVE: Low-level viraemia (LLV) occurs in some people with HIV (PWH) receiving antiretroviral th...
Objectives: Characterization of the conditions favouring HIV-1 low-level viraemia (LLV) during treat...
BackgroundThe clinical management of low-level viremia (LLV) remains unclear. The objective of this ...
Background: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortalit...
Introduction: Low-level viraemia (LLV) is observed in some patients with HIV-1 infection on stable a...
BACKGROUND: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortalit...
Retrospective analysis of 22 523 people with HIV-1 receiving antiretroviral therapy indicates that b...
Introduction: For some patients, it remains a challenge to achieve complete virological suppression ...
BACKGROUND: It is unclear whether low-level viremia (LLV), defined as repeatedly detectable viral lo...
In human immunodeficiency virus treatment adequate virological suppression is warranted, nevertheles...
To identify host and viral characteristics associated with long-term persisting low-level viraemia (...
BACKGROUND: In human immunodeficiency virus treatment adequate virological suppression is warranted,...
Background: The rate, predictors and outcome following episodes of low-level viral rebound (LLVR) in...
BACKGROUND: Management of persistent low-level viraemia (pLLV) in patients on combined antiretrovira...
Background: Few individuals commencing antiretroviral therapy (ART) in primary HIV infection (PHI) m...
OBJECTIVE: Low-level viraemia (LLV) occurs in some people with HIV (PWH) receiving antiretroviral th...
Objectives: Characterization of the conditions favouring HIV-1 low-level viraemia (LLV) during treat...
BackgroundThe clinical management of low-level viremia (LLV) remains unclear. The objective of this ...
Background: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortalit...
Introduction: Low-level viraemia (LLV) is observed in some patients with HIV-1 infection on stable a...
BACKGROUND: The goal of antiretroviral therapy (ART) is to reduce HIV-related morbidity and mortalit...
Retrospective analysis of 22 523 people with HIV-1 receiving antiretroviral therapy indicates that b...
Introduction: For some patients, it remains a challenge to achieve complete virological suppression ...
BACKGROUND: It is unclear whether low-level viremia (LLV), defined as repeatedly detectable viral lo...
In human immunodeficiency virus treatment adequate virological suppression is warranted, nevertheles...
To identify host and viral characteristics associated with long-term persisting low-level viraemia (...
BACKGROUND: In human immunodeficiency virus treatment adequate virological suppression is warranted,...
Background: The rate, predictors and outcome following episodes of low-level viral rebound (LLVR) in...
BACKGROUND: Management of persistent low-level viraemia (pLLV) in patients on combined antiretrovira...
Background: Few individuals commencing antiretroviral therapy (ART) in primary HIV infection (PHI) m...